In our NGS lab, the hardest part of scaling has not been robots; it is change control. A tiny edit to a liquid handler method or a PCR cycling profile can shift QC metrics and downstream calling. If that change is not traceable, root cause hunts get painful and expensive.
What helped: treating wet lab methods like software. Every assay step has a version and a short changelog. We link each run to method version, instrument firmware, and reagent lot in the LIMS. We test changes in a sandbox lane with synthetic controls before promotion. It slowed us at first but cut CAP audit time and reduced unexplained failures.
The tradeoff is agility. Too much gating and teams route around the process; too little and you lose provenance. Where have you landed? Practical tips for balancing rapid iteration with ISO 13485 and CLIA without paralyzing the team?
At Helix we use risk-tiered change control aligned to ISO 13485/14971: Tier 1 UI/labels same day, Tier 2 params within validated bounds with SME plus single-lane validation, Tier 3 chemistry/thermocycle/firmware with full V&V and lot-bridging. We freeze method code and only allow Git-tracked parameter files with PRs, and ship on a weekly release train with an emergency hotfix path. Each promotion runs a pilot plate of synthetic and Genome in a Bottle controls across instruments with SPC dashboards in the LIMS, which flags drift quickly without slowing the team.